Project publications

  1. Abeywickrama-Samarakoon N, Cortay JC, Sureau C, Müller S, Alfaiate D, Guerrieri F, Chaikuad A, Schröder M, Merle P, Levrero M,
    Dény P. (2020).
    Hepatitis Delta Virus histone mimicry drives the recruitment of chromatin remodelers for viral RNA replication.
    Nat Commun. 2020 Jan 21;11(1):419.
  2. Aizarani N, Saviano A, Sagar, Mailly L, Durand S, Herman JS, Pessaux P, Baumert TF and Grun D. (2019).
    A human liver cell atlas reveals heterogeneity and epithelial progenitors.
    Nature. 572, 199-204.
  3. Appelman MD, Chakraborty A, Protzer U, McKeating JA and van de Graaf, SFJ. (2017).
    N-Glycosylation of the Na+-Taurocholate Cotransporting Polypeptide (NTCP) Determines Its Trafficking and Stability and Is Required for Hepatitis B Virus Infection.
    Plos ONE. 12(1):e0170419.
  4. Bandiera S, Pernot S, El Saghire H, Durand SC, Thumann C, Crouchet E, Ye T, Fofana I, Oudot MA, Barths J, Schuster C, Pessaux P, Heim MH, Baumert TF, Zeisel MB. (2016).
    Hepatitis C Virus-Induced Upregulation of MicroRNA miR-146a-5p in Hepatocytes Promotes Viral Infection and Deregulates Metabolic Pathways Associated with Liver Disease Pathogenesis.
    J Virol. 90, 6387-400.
  5. Bandiera S, Billie Bian C., Hoshida Y, Baumert TF and Zeisel MB. (2016a).
    Chronic hepatitis C virus infection and pathogenesis of hepatocellular carcinoma.
    Curr Opin Virol. 20, 99-105. Review
  6. Baumert TF, Jühling F, Ono A, Hoshida Y. (2017).
    Hepatitis C-related hepatocellular carcinoma in the era of new generation antivirals.
    BMC Med. 5(1):52. Review
  7. Baumert TF, Berg T, Lim JK, Nelson DR. (2018).
    Status of Direct-acting Antiviral Therapy for HCV Infection and Remaining Challenges.
    Gastroenterology. 156, 431-445. Review.
  8. Baumert TF and Hoshida Y. (2019).
    Addressing the challenges of hepatitis c cure and persistent risk of hepatocellular carcinoma.
    Viruses. May 15;11(5). Review.
  9. Bollard J, Miguela V, Ruiz de Galarreta M, Venkatesh A, Bian CB, Roberto MP, Tovar V, Sia D, Molina-Sánchez P, Nguyen CB, Nakagawa S, Llovet JM, Hoshida Y, Lujambio A.(2016).
    Palbociclib (PD-0332991), a selective CDK4/6 inhibitor, restricts tumour growth in preclinical models of hepatocellular carcinoma.
    Gut. 66/7, 1286-1296.
  10. Bou About G, Thiebault E, Wattenhofer-Donzé M, Jacobs H, Guimond A, Sorg T, Robinet E, Baumert TF, Monassier L, Herault Y. (2019).
    Ultrasound-Guided Approaches to Improve Orthotopic Mouse Xenograft Models for Hepatocellular Carcinoma.
    Curr Protoc Mouse Biol. Jun;9(2):e62.
  11. Cardo L, Nawroth I, Cail PJ, McKeating JA and Hannon MJ. (2018).
    Metallo supramolecular cylinders HIV-1 TAR-TAT complex formation and viral infection in cellulo.
    Science Reports. 8:13342.
  12. Colpitts CC, Tawar RG, Mailly L, Thumann C, Heydmann L, Durand SC, Xiao F, Robinet E, Pessaux P, Zeisel MB, Baumert TF. (2017).
    Humanisation of a claudin-1-specific monoclonal antibody for clinical prevention and cure of HCV infection without escape.
    Gut. Apr;67(4):736-745
  13. Colpitts CC, and Baumert TF. (2016).
    Hepatitis C virus cell entry: a target for novel antiviral strategies to address limitations of direct acting antivirals.
    Hepatol. Int. Sep;10(5):741-8. Review
  14. Colpitts CC, Lupberger J, Baumert TF. (2016).
    Multifaceted role of E-cadherin in hepatitis C virus infection and pathogenesis.
    Proc Natl Acad Sci U S A. Jul 5;113(27):7298-300. Review.
  15. Colpitts CC, Baumert TF. (2017).
    SMAD about hepatitis C virus cell entry and liver disease.
    Gastroenterology. Jan;152(1):21-23. Review.
  16. Colpitts CC, Baumert TF. (2017).
    SCARB1 variants and HCV infection: Host susceptibility is lost in translation.
    J Hepatol. Aug;67(2):211-213. Review.
  17. Colpitts CC, Baumert TF. (2017).
    Claudins in viral infection: from entry to spread.
    Pflugers Arch. Jan;469(1):27-34. Review..
  18. Colpitts CC, Chung RT, Baumert TF. (2017).
    Entry Inhibitors: A Perspective for Prevention of Hepatitis C Virus Infection in Organ Transplantation.
    ACS Infect Dis. Sep 8;3(9):620-623. Review.
  19. Crouchet E, Lefèvre M, Verrier ER, Oudot MA, Baumert TF, Schuster C. (2017).
    Extracellular lipid-free apolipoprotein E inhibits HCV replication and induces ABCG1-dependent cholesterol efflux.
    Gut. May;66(5):896-907.
  20. Crouchet E, Wrensch F, Zeisel M, Schuster C, Baumert TF. (2018).
    Host-targeting therapies for hepatitis C virus infection: current developments and future applications.
    Therapeutic Advances in Gastroenterology. Mar 21;11:1756284818759483. Review.
  21. D’Arienzo V, Magri A, Harris JH, Wing PAC, Ko C, Orbegozo Rubio C, Peter A Revill PA,Protzer U, Balfe P and McKeating JA. (2019).
    A PCR assay to quantify patterns of HBV transcription.
    J Gen Virol. Mar 21;11:1756284818759483. Review.
  22. Desombere I, Mesalam AA, Urbanowicz RA, Van Houtte F, Verhoye L, Keck ZY, Farhoudi A, Vercauteren K, Weening KE, Baumert TF, Patel AH, Foung SKH, Ball J, Leroux-Roels G, Meuleman P. (2017).
    A novel neutralizing human monoclonal antibody broadly abrogates hepatitis C virus infection in vitro and in vivo.
    Antiviral res. Dec;148:53-64.
  23. Eller C, Heydmann L, Colpitts CC, Verrier ER, Schuster C, Baumert TF. (2018).
    The functional role of sodium taurocholate cotransporting polypeptide NTCP in the life cycle of hepatitis B, C and D viruses.
    Cell Mol Life Sci. Nov;75(21):3895-3905. Review.
  24. Elßner C, Goeppert B, Longerich T, Scherr AL, Stindt J, Nanduri LK, Rupp C, Kather JN, Schmitt N, Kautz N, Breuhahn K, Ismail L, Heide D, Hetzer J, García-Beccaria M, Hövelmeyer N, Waisman A, Urbanik T, Mueller S0, Gdynia G, Banales JM, Roessler S, Schirmacher P, Jäger D, Schölch S, Keitel V, Heikenwalder M, Schulze-Bergkamen H, Köhler BC. (2018).
    Nuclear Translocation of RELB is Increased in Diseased Human Liver and Promotes Ductular Reaction and Biliary Fibrosis in Mice.
    Gastroenterology. 156 (4), 1190–1205.e14.
  25. Farquhar MJ, Humphreys IS, Rudge SA, Wilson GK, Bhattacharya B, Ciaccia M, Hu K, Zhang Q, Mailly L, Reynolds GM, Ashcroft M, Balfe P, Baumert TF, Roessler S, Wakelam MJO, McKeating JA. (2017).
    Autotaxin-lysophosphatidic acid receptor signalling regulates hepatitis C virus replication.
    J Hepatol. 66, 919-929.
  26. Fauvelle C, Colpitts CC, Keck ZY, Pierce BG, Foung SK, and Baumert TF. (2016).
    Hepatitis C virus vaccine candidates inducing protective neutralizing antibodies.
    Expert Rev. Vaccines. Dec;15(12):1535-1544. Review.
  27. Felmlee D., Grun D and Baumert TF. (2018).
    Zooming in on liver zonation.
    Hepatology. Feb;67(2):784-787. Review.
  28. Foung SKH and Baumert TF. (2018).
    Editorial: Current progress and challenges in the development of a B cell based hepatitis C virus vaccine.
    Front Immunol. Nov 9;9:2577. Review.
  29. Galle PR, Forner A, Llovet JM, Mazzaferro V, Piscaglia F, Raoul J-L, Schirmacher P, Vilgrain V. (2018).
    EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma, European Association for the Study of the Liver.
    J Hepatol. 69:182-236.
  30. Georgilis A, Klotz S, Hanley CJ, Herranz N, Weirich B, Morancho B, Leote AC, D'Artista L, Gallage S, Seehawer M, Carroll T, Dharmalingam G, Wee KB, Mellone M, Pombo J, Heide D, Guccione E, Arribas J, Barbosa-Morais NL, Heikenwalder M, Thomas GJ, Zender L, Gil J. (2018).
    PTBP1-Mediated Alternative Splicing Regulates the Inflammatory Secretome and the Pro-tumorigenic Effects of Senescent Cells.
    Cancer Cell. 34(1):85-102.e9.
  31. Gehring A and Protzer U. (2019)
    Targeting Innate and Adaptive Immune Responses to Cure Chronic HBV Infection.
    Gastroenterology. Jan;156(2):325-337. PMID 30367834.
  32. Goeppert B, Toth R, Singer S, Albrecht T, Lipka DB, Lutsik P, Brocks D, Baehr M, Muecke O, Assenov Y, Gu L, Endris V, Stenzinger A, Mehrabi A, Schirmacher P, Plass C, Weichenhan D, Roessler S. (2019).
    Integrative analysis defines distinct prognostic subgroups of intrahepatic cholangiocarcinoma.
    Hepatology. 69 (5), 2091-2106.
  33. Goeppert B*, Folseraas T*, Roessler*, Kloor M, Volckmar AL, Endris V, Buchhalter I, Stenzinger A, Grzyb K, Grimsrud MM, Gornicka B, von Seth E, Reynolds GM, Franke A, Gotthardt DN, Mehrabi A, Cheung A, Verheij J, Arola J, Mäkisalo H, Eide TJ, Weidemann S, Cheville JC, Mazza G, Hirschfield GM, Ponsioen CY, Bergquist A, Milkiewicz P, Lazaridis KN, Schramm C, Manns MP, Färkkilä M, Vogel A, International PSC study group, Boberg KM, Schirmacher P, Karlsen TH (2019).
    Genomic characterization of cholangiocarcinoma in primary sclerosing cholangitis reveals novel therapeutic opportunities.
    Hepatology. 2020 Jan 10. doi: 10.1002/hep.31110. [Epub ahead of print].
  34. Gonçalves-Carneiro D, McKeating JA and Bailey D. (2017).
    The Measles Virus Receptor SLAMF1 Can Mediate Particle Endocytosis.
    J Virology. 91/7, e02255-16.
  35. Grove J, Hu K, Farquhar MJ, Goodall M, Walker L, Jamshad M, Drummer HE, Bill RM, Balfe P and McKeating JA. (2017).
    A new panel of epitope mapped monoclonal antibodies recognizing the prototypical tetraspanin CD81.
    Wellcome Open Research. 2:82.
  36. Hamdane N, Jühling F, Crouchet E, El Saghire H, Thumann C, Oudot M, Bandiera S, Saviano A, Ponsolles C, Roca Suarez AA, Li S, Fujiwara N, Ono A, Davidson I, Bardeesy N, Schmidl C, Bock C, Schuster C, Lupberger J, Habersetzer F, Doffoël M, Piardi T, Sommacale D, Imamura M, Uchida T, Ohdan H, Aikata H, Chayama K, Boldanova T, Pessaux P, Fuchs BC, Hoshida Y, Zeisel MB, Duong FHT, Baumert TF. (2019).
    HCV-induced epigenetic changes associated with liver cancer risk persist after sustained virologic response.
    Gastroenterology. Jun;156(8):2313-2329.e7
  37. Haqshenas G, Wu J, Simpson KJ, Daly RJ, Netter HJ, Baumert TF, Doerig C. (2017).
    Signalome-wide assessment of host cell response to hepatitis C virus.
    Nat Commun. May 8;8:15158.
  38. Herzog K, Bandiera S, Pernot S, Fauvelle C, Jühling F, Weiss A, Bull A, Durand SC, Chane-Woon-Ming B, Pfeffer S, Mercey M, Lerat H, Meunier J-C, Raffelsberger W, Brino L, Baumert TF, Zeisel MB. (2019).
    Functional microRNA screen uncovers O-linked N-acetylglucosamine transferase as a host factor modulating hepatitis C virus morphogenesis and infectivity.
    Gut. May 10.
  39. Hösel M, Quasdorff M, Ringelhan M, Kashkar H, Debey-Pascher S, Sprinzl MF, BockmannJH, ArzbergerA, Webb D, von Olshausen G, Weber A, Schultze JL, Büning H, Heikenwalder M, Protzer, U. (2017).
    Signalome-wide assessment of host cell response to hepatitis C virus.
    Cellular and Molecular Gastroenterology and Hepatology. 4: 339-363.
  40. Hu J, Protzer U, Siddiqui A. (2019).
    Revisting hepatitis B Virus: Challenges of Curative Therapies.
    Journal of Virology. Aug; PMID 31399106.
  41. Jühling F, Verrier ER, Saviano A , El Saghire H, Heydmann H, Pessaux P, Pochet N, Schuster C, Baumert TF.
    Single-cell RNA-Seq of HBV-induced hepatocellular carcinoma reveals viral compartmentalization and cancer heterogeneity.
    J Clin Invest. in revision.
  42. Keck ML, Wrensch F, Pierce BG, Baumert TF, Foung S. (2018).
    Mapping determinants of virus neutralization and viral escape for rational design of a hepatitis C virus vaccine.
    Frontiers in Immunology. May 31;9:1194. Review.
  43. Khera T, Todt D, Vercauteren K, McClure CP, Verhoye L, Farhoudi A, Bhuju S, Geffers R, Baumert TF, Steinmann E, Meuleman P,
    Pietschmann T, Brown RJ. (2017).
    Tracking HCV protease population diversity during transmission and susceptibility of founder populations to antiviral therapy.
    Antiviral Research. Jan 3;139, 129-137.
  44. Ko C, Chakraborty A, Chou WM, Hasreiter J, Wettengel JM, Stadler D, Bester R, Asen T, Zhang K, Wisskirchen K, McKeating JA, Ryu WS, Protzer U. (2018).
    Hepatitis B virus genome recycling and de novo secondary infection events maintain stable cccDNA levels.
    Journal of Hepatology. 69 (6), 1231-1241.
  45. Ko C, Bester R, Zhou X, Xu Z, Blossey C, Sacherl J, Vondran FWR, Gao L, Protzer U. (2019)
    A new role for capsid assembly modulators to target mature hepatitis B virus capsids and prevent virus infection.
    Antimicrob Agents Chemother. Oct 28. doi: 10.1128/AAC.01440-19. [Epub ahead of print]; PMID: 31658963.
  46. Labgaa I, Villacorta-Martin C, D'Avola D, Craig AJ, von Felden J, Martins-Filho SN, Sia D, Stueck A, Ward SC, Fiel MI, Mahajan M, Tabrizian P, Thung SN, Ang C, Friedman SL, Llovet JM, Schwartz M, Villanueva A. (2018).
    A pilot study of ultra-deep targeted sequencing of plasma DNA identifies driver mutations in hepatocellular carcinoma.
    Oncogene. 37:3740-3752.
  47. Lai AG, Forde D, Chang WH, Zhuang X Rubio CO, Balfe P and McKeating JA. (2018).
    Glucose and glutamine availability regulate HepG2 hepatoma transcriptional responses.
    Wellcome Open Research. 3:126.
  48. Lencioni R, Montal R, Torres F, Park JW, Decaens T, Raoul JL, Kudo M, Chang C, Ríos J, Boige V, Assenat E, Kang YK, Lim HY, Walters I, Llovet JM. (2017).
    Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC.
    J Hepatol. 66/6, 1166-1172.
  49. Levrero M, Subic M, Villeret F, Zoulim F. (2018).
    Perspectives and limitations for nucleo(t)side analogs in future HBV therapies.
    Curr Opin Virol. 2018 Jun;30:80-89. Review
  50. Levrero M, Zucman-Rossi J. (2016).
    Mechanisms of HBV-induced hepatocellular carcinoma.
    J Hepatol. 2016 Apr;64(1 Suppl):S84-S101. Review
  51. Li C, Wang Y, Liu T, Niklasch M, Qiao K, Durand S, Chen L, Liang M, Baumert TF, Tong S, Nassal M, Wen YM, Wang YX. (2019)
    An E. coli-produced single-chain variable fragment (scFv) targeting hepatitis B virus surface protein potently inhibited virion secretion.
    Antiviral res. Feb;162:118-129.
  52. Li Y, Xia Y, Han M, Chen G, Zhang D, Thasler W, Protzer U, Ning Q. (2017).
    IFN-α-mediated Base Excision Repair Pathway Correlates with Antiviral Response Against Hepatitis B Virus Infection.
    Scientific Reports. Oct 5;7(1):12715.
  53. Ligat G., Schuster C., Baumert T.F. (2019).
    HBV core variants, liver fibrosis and hepatocellular carcinoma.
    Hepatology. Jan;69(1):5-8. Review.
  54. Lim TR, Hazelhurst J, Oprescu AI, Armstrong MJ, Abdullah SF, Davies NP, Flintham R, Balfe P, Mutimer DJ, McKeating JA and Tomlinson, JW. (2018).
    Hepatitis C virus infection is associated with hepatic and adipose tissue insulin resistance that improves post viral cure.
    Clin Endocrinolgy. 90 (3), 440-448.
  55. Llovet JM, Zucman-Rossi J, Pikarsky E, Sangro B, Schwartz M, Sherman M, Gores G. (2016).
    Hepatocellular carcinoma.
    Nat Rev Dis Primers. 2:16018.
  56. Llovet JM, Montal R, Sia D, Finn S. (2018).
    Molecular therapies and precision medicine for hepatocellular carcinoma.
    Nat Rev Clin Oncol. 15:599-616.
  57. Llovet JM, Pavel M, Rimola J, Diaz MA, Colmenero J, Saavedra-Perez D, Fondevila C, Ayuso C, Fuster J, Ginès P, Bruix J, Garcia-Valdecasas JC. (2018).
    Pilot study of living donor liver transplantation for patients with hepatocellular carcinoma exceeding Milan Criteria (Barcelona Clinic Liver Cancer extended criteria).
    Liver Transpl. 24:369-379.
  58. Llovet JM, Montal R, Villanueva A. (2019).
    Randomized trials and endpoints in advanced HCC: Role of PFS as a surrogate of survival.
    J. Hepatol. 70(6):1262-1277.
  59. Lorentzen A, Becker PF, Kosla J, Saini M, Weidele K, Ronchi P, Klein C, Wolf MJ, Geist F, Seubert B, Ringelhan M, Mihic-Probst D, Esser K, Roblek M, Kuehne F, Bianco G, O'Connor T, Müller Q, Schuck K, Lange S, Hartmann D, Spaich S, Groß O, Utikal J, Haferkamp S, Sprick MR, Damle-Vartak A, Hapfelmeier A, Hüser N, Protzer U, Trumpp A, Saur D, Vartak N, Klein CA, Polzer B, Borsig L, Heikenwalder M. (2018).
    Single cell polarity in liquid phase facilitates tumour metastasis.
    Nature Communications. 9(1):887.
  60. Luiken S, Fraas A, Bieg M, Sugiyanto R, Goeppert B, Singer S, Ploeger C, Warsow G, Marquardt JU, Sticht C, De La Torre C, Pusch S, Mehrabi A, Gretz N, Schlesner M, Eils R, Schirmacher P, Longerich T, Roessler S.
    NOTCH target gene HES5 mediates oncogenic and tumor suppressive functions in hepatocarcinogenesis.
    Oncogene. conditionally accepted.
  61. Lupberger J, Croonenborghs T, Roca Suarez AA, Van Renne N, Jühling F, Oudot MA, Virzì A, Bandiera S, Jamey C, Meszaros G, Brumaru D, Mukherji A, Durand SC, Heydmann L, Verrier ER, El Saghire H, Hamdane N, Bartenschlager R, Fereshetian S, Ramberger E, Sinha R, Nabian M, Everaert C, Jovanovic M, Mertins P, Carr SA, Chayama K, Dali-Youcef N, Ricci R, Bardeesy NM, Fujiwara N, Gevaert O, Zeisel MB, Hoshida Y, Pochet N, Baumert TF. (2019).
    Combined analysis of metabolomes, proteomes, and transcriptomes of hepatitis c virus-infected cells and liver to identify pathways associated with disease development.
    Gastroenterology. Aug;157(2):537-551.e9.
  62. Mailly L, Wrensch F, Heydmann L, Fauvelle C, Brignon N, Zeisel MB, Pessaux P, Keck ZY, Schuster C, Fuerst TR, Foung SKH, Baumert TF. (2019).
    In vivo combination of human anti-envelope glycoprotein E2 and -Claudin-1 monoclonal antibodies for prevention of hepatitis C virus infection.
    Antiviral res. Feb;162:136-141.
  63. Mailly L, Zeisel MB, and Baumert TF. (2017).
    Toward novel immunocompetent animal models for hepatitis B virus infection.
    Hepatology. Sep;66(3):691-693. Review.
  64. Majzoub K, Wrensch F and Baumert TF. (2019).
    The Innate Antiviral Response in Animals: An Evolutionary Perspective from Flagellates to Humans.
    Viruses. Aug 16;11(8). Review.
  65. Manzoni G, Marinach C, Topçu S, Briquet S, Grand M, Tolle M, Gransagne M, Lescar J, Andolina C, Franetich JF, Zeisel MB, Huby T, Rubinstein E, Snounou G, Mazier D, Nosten F, Baumert TF, Silvie O. (2017).
    Plasmodium P36 determines host cell receptor usage during sporozoite invasion.
    eLife. 6. pii: e25903.
  66. Martinez-Quetglas I, Pinyol R, Dauch D, Torrecilla S, Tovar V, Moeini A, Alsinet C, Portela A, Rodriguez-Carunchio L, Solé M, Lujambio A, Villanueva A, Thung S, Esteller M, Zender L, Llovet JM. (2016).
    IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models.
    Gastroenterology 151(6):1192-1205.
  67. McNaughton AL, D’Arienzo V, Ansari A, Lumley S, Littlejohn M, Revill P, McKeating JA and Matthews, PC. (2018).
    Insights From Deep Sequencing of the HBV Genome-Unique, Tiny, and Misunderstood.
    Gastroenterology 156; 384-399.
  68. Moeini A, Sia D, Zhang Z, Camprecios G, Stueck A, Dong H, Montal R, Torrens L, Martinez-Quetglas I, Fiel MI, Hao K, Villanueva A, Thung SN, Schwartz ME, Llovet JM. (2017).
    Mixed hepatocellular cholangiocarcinoma tumors: Cholangiolocellular carcinoma is a distinct molecular entity.
    J Hepatol. 66(5):952-961.
  69. Moeini A, Sia D, Bardeesy N, Mazzaferro V, Llovet JM. (2016).
    Molecular Pathogenesis and Targeted Therapies for Intrahepatic Cholangiocarcinoma.
    Clin Cancer Res. 22(2):291-300.
  70. Moeini A, Torrecilla S, Tovar V, Montironi C, Andreu-Oller C, Peix J, Higuera M, Pfister D, Ramadori P, Pinyol R, Solé M, Heikenwälder M, Friedman SL, Sia D, Llovet JM. (2019)
    An Immune Gene Expression Signature Associated With Development of Human Hepatocellular Carcinoma Identifies Mice That Respond to Chemopreventive Agents.
    Gastroenterology. 157(5):1383-1397.
  71. Malehmir M, Pfister D, Gallage S, Szydlowska M, Inverso D, Kotsiliti E, Leone V, Peiseler M, Surewaard BGJ, Rath D, Ali A, Wolf MJ, Drescher H, Healy ME, Dauch D, Kroy D, Krenkel O, Kohlhepp M, Engleitner T, Olkus A, Sijmonsma T, Volz J, Deppermann C, Stegner D, Helbling P, Nombela-Arrieta C, Rafiei A, Hinterleitner M, Rall M, Baku F, Borst O, Wilson CL, Leslie J, O'Connor T, Weston CJ, Adams DH, Sheriff L, Teijeiro A, Prinz M, Bogeska R, Anstee N, Bongers MN, Notohamiprodjo M, Geisler T, Withers DJ, Ware J, Mann DA, Augustin HG, Vegiopoulos A, Milsom MD, Rose AJ, Lalor PF, Llovet JM, Pinyol R, Tacke F, Rad R, Matter M, Djouder N, Kubes P, Knolle PA, Unger K, Zender L, Nieswandt B, Gawaz M, Weber A, Heikenwalder M. (2019).
    Platelet GPIba is a mediator and potential interventional target for NASH and subsequent liver cancer.
    Nature Medicine. 25(4):641-655.
  72. Montal R, Andreu-Oller C, Bassaganyas L, Esteban-Fabró R, Moran S, Montironi C, Moeini A, Pinyol R, Peix J, Cabellos L, Villanueva A, Sia D, Mazzaferro V, Esteller M, Llovet JM. (2019).
    Molecular portrait of high alpha-fetoprotein in hepatocellular carcinoma: implications for biomarker-driven clinical trials.
    British Journal of Cancer. 121(4):340-343.
  73. Mukherji A, Bailey SM, Staels B, and Baumert TF. (2019).
    The circadian clock and liver function in health and disease.
    J Hepatol. Jul;71(1):200-211. Review.
  74. Nunn AD, Scopigno T, Pediconi N, Levrero M, Hagman H, Kiskis J, Enejder A. (2016).
    The histone deacetylase inhibiting drug Entinostat induces lipid accumulation in differentiated HepaRG cells.
    Sci Rep. 2016 Jun 20;6:28025.
  75. Pinyol R, Montal R, Bassaganyas L, Sia D, Takayama T, Chau GY, Mazzaferro V, Roayaie S, Lee HC, Kokudo N, Zhang Z, Torrecilla S, Moeini A, Rodriguez-Carunchio L, Gane E, Verslype C, Croitoru AE, Cillo U, de la Mata M, Lupo L, Strasser S, Park JW, Camps J, Solé M, Thung SN, Villanueva A, Pena C, Meinhardt G, Bruix J, Llovet JM. (2019).
    Molecular predictors of prevention of recurrence in HCC with sorafenib as adjuvant treatment and prognostic factors in the phase 3 STORM trial.
    Gut. 68(6):1065-107.
  76. Pinyol R, Sia D, Llovet JM. (2019).
    Immune Exclusion-Wnt/CTNNB1 Class Predicts Resistance to Immunotherapies in HCC.
    Clin. Cancer. Res. 25(7):2021-2023.
  77. Plissonnier ML, Herzog K, Levrero M, Zeisel MB. (2018).
    Non-Coding RNAs and Hepatitis C Virus-Induced Hepatocellular Carcinoma.
    Viruses 2018 Oct 30;10(11):591. Review
  78. Protzer U. (2017).
    Viral hepatitis: The bumpy road to animal models for HBV infection.
    Nature Reviews in Gastroenterology and Hepatology. 14(6):327-328.
  79. Ramadori P, Klag T, Malek NP, Heikenwalder M. (2019).
    Platelets in chronic liver disease, from bench to bedside.
    JHEP Rep. 1(6):448-459.
  80. Ringelhan, M, McKeating JA and Protzer U. (2017).
    Viral hepatitis and liver cancer.
    Phil Trans Royal Society. 372(1732).
  81. Ringelhan M, Pfister D, O'Connor T, Pikarsky E, Heikenwalder M. (2018).
    The immunology of hepatocellular carcinoma.
    Nature Immunology. 19(3):222-232. Epub 2018 Jan 29. Review.
  82. Roca Suarez AA, Van Renne N, Baumert TF, Lupberger J. (2018).
    Viral manipulation of STAT3: evade, exploit and injure.
    Plos Pathogens. 14(3):e1006839. eCollection 2018 Mar. Review.
  83. Roca Suarez AA, Baumert TF, Lupberger J. (2018).
    Beyond viral dependence: the pathological consequences of HCV-induced EGF signaling.
    J. Hepatol. 69(3):564-566. Review.
  84. Roehlen N and Baumert TF. (2019).
    Uncovering the mechanism of action of aspirin in HCC chemoprevention.
    EBioMedicine. Aug;46:21-22. Review.
  85. Ruiz de Galarreta M, Bresnahan E, Molina-Sanchez P, Lindblad KE, Maier B, Sia D, Puigvehi M, Miguela V, Casanova-Acebes M, Dhainaut M, Villacorta-Martin C, Singhi AD, Moghe A, von Felden J, Grinspan LT, Wang S, Kamphorst AO, Monga SP, Brown BD, Villanueva A, Llovet JM, Merad M, Lujambio A. (2019).
    Beta-Catenin Activation Promotes Immune Escape and Resistance to Anti-PD-1 Therapy in Hepatocellular Carcinoma.
    Cancer Discovery. 9(8):1124-1141.
  86. Salerno D, Chiodo L, Alfano V, Floriot O, Cottone G, Paturel A, Pallocca M, Plissonnier ML, Jeddari S, Belloni L, Zeisel M, Levrero M,
    Guerrieri F. (2020).
    Hepatitis B protein HBx binds the DLEU2 lncRNA to sustain cccDNA and host cancer-related gene transcription.
    Gut. 2020 Feb 29:gutjnl-2019-319637. doi: 10.1136/gutjnl-2019-319637. Epub ahead of print. PMID: 32114505.
  87. Saviano A and Baumert TF. (2019).
    Mortality from liver cirrhosis and HCC in the DAA era: success in viral control is darkened by raise of metabolic disease.
    HepatoBiliary Surg Nutr. Jun;8(3):307-310. Review.
  88. Sia D, Jiao Y, Martinez-Quetglas I, Kuchuk O, Villacorta-Martin O, Castro de Moura M, Putra J, Camprecios G, Bassaganyas L, Akers N, Losic B, Waxman S, Thung SN, Mazzaferro V, Esteller M, Friedman SL, Schwartz M, Villanueva A, Llovet, J.M. (2017).
    Identification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features.
    Gastroenterology. 153(3):812-826.
  89. Sia D, Villanueva A, Friedman SL, Llovet JM. (2017).
    Liver Cancer Cell of Origin, Molecular Class, and Effects on Patient Prognosis.
    Gastroenterology. 152:745-761.
  90. Schwenzer H, Jühling F, Chu A, Pallett LJ, Baumert TF, Maini M, Fassati A. (2019).
    Oxidative Stress Triggers Selective tRNA Retrograde Transport in Human Cells during the Integrated Stress Response.
    Cell reports. Mar 19;26(12):3416-3428.e5.
  91. Sia D, Llovet JM. (2017).
    Liver cancer: Translating '-omics' results into precision medicine for hepatocellular carcinoma.
    Nat Rev Gastroenterol Hepatol. 14:571-572.
  92. Smits M, Zoldan K, Ishaque N, Gu Z, Jechow K, Wieland D, Conrad C, Eils R, Fauvelle C, Baumert TF, Emmerich F, Bengsch B, Neumann-Haefelin C, Hofmann M, Thimme R, Boettler T. (2019).
    Follicular T helper cells shape the HCV-specific CD4 T cell repertoire after viral elimination.
    J Clin Invest. 130 (2); 998-1009.
  93. Taouli B, Hoshida Y, Kakite S, Chen X, Tan PS, Sun X, Kihira S, Kojima K, Toffanin S, Fiel MI, Hirschfield H, Wagner M, Llovet JM. (2017).
    Imaging-based surrogate markers of transcriptome subclasses and signatures in hepatocellular carcinoma: preliminary results.
    Eur Radiol. 27(11):4472-4481.
  94. Tauber C, Schultheiss M, Luca R De, Buettner N, Llewellyn-Lacey S, Emmerich F, Zehe S, Price DA, Neumann-Haefelin C, Schmitt-Graeff A, Hofmann M, Thimme R. (2019).
    Inefficient induction of circulating TAA-specific CD8+ T-cell responses in hepatocellular carcinoma.
    Oncotarget. 2019; 10: 5194-5206.
  95. Tawar RG, Heydmann L, Bach C, Schüttrumpf J, Chavan S, King BJ, McClure CP, Ball JK, Pessaux P, Habersetzer F, Bartenschlager R, Zeisel MB, Baumert TF. (2016).
    Broad neutralization of hepatitis C virus-resistant variants by Civacir hepatitis C immunoglobulin.
    Hepatology. Nov;64(5):1495-1506.
  96. Testoni B, Levrero M, Zoulim F. (2017).
    Challenges to a Cure for HBV Infection.
    Semin Liver Dis. 2017 Aug;37(3):231-242. Review
  97. Thomas E and Baumert TF. (2019).
    Hepatitis B Virus-Hepatocyte Interactions and Innate Immune Responses: Experimental Models and Molecular Mechanisms.
    Semin Liver Dis. Jul;39(3):301-314. Review.
  98. Torrecilla S, Sia D, Harrington AN, Zhang Z, Cabellos L, Cornella H, Moeini A, Camprecios G, Leow WQ, Fiel MI, Hao K, Bassaganyas L, Mahajan M, Thung SN, Villanueva A, Florman S, Schwartz ME, Llovet JM. (2017).
    Trunk events present minimal intra- and inter-tumoral heterogeneity in hepatocellular carcinoma.
    JJ. Hepatol. 67:1222-1231.
  99. Tovar V, Cornella H, Moeini A, Vidal S, Hoshida Y, Sia D, Peix J, Cabellos L,  Alsinet C, Torrecilla S, Martinez-Quetglas I, Lozano JJ, Desbois-Mouthon C, Solé  M, Domingo-Domenech J, Villanueva A, Llovet JM. (2017).
    Tumour initiating cells and IGF/FGF signalling contribute to sorafenib resistance in hepatocellular carcinoma.
    Gut. Mar;66(3):530-540.
  100. Van Renne N, Roca Suarez AA, Duong FHT, Gondeau C, Calabrese D, Fontaine N, Ababsa A, Bandiera S, Croonenborghs T, Pochet N, De Blasi V, Pessaux P, Piardi T, Sommacale D, Ono A, Chayama K, Fujita M, Nakagawa H, Hoshida Y, Zeisel MB, Heim MH, Baumert TF, Lupberger J. (2017).
    miR-135a-5p-mediated downregulation of protein-tyrosine phosphatase delta is a candidate driver of HCV-associated hepatocarcinogenesis.
    Gut. May;67(5):953-962.
  101. Verrier ER, Colpitts CC, Schuster C, Zeisel MB and Baumert TF. (2016b).
    Cell culture models for the investigation of hepatitis B and D virus infection.
    Viruses. Sep 20;8(9). Review.
  102. Verrier ER, Colpitts CC, Sureau, C, and Baumert TF. (2016c).
    Hepatitis B virus receptors and molecular drug targets.
    Hepatol. Int. Jul;10(4):567-73. Review.
  103. Verrier ER, Colpitts CC, Zona L, Bach C, Heydmann L, Xiao F, Thumann C, Schuster C, Sureau C, McKeating JA, Hoshida Y, Zeisel MB and Baumert TF. (2017).
    Solute carrier NTCP regulates expression of innate antiviral immune responses targeting viral cell entry into hepatocytes.
    Cell Reports. Oct 25;17(5):1357-1368.
  104. Verrier ER, Schuster C, Baumert TF. (2017).
    Advancing hepatitis B virus entry inhibitors.
    J. Hepatol. Apr;66(4):677-679. Review.
  105. Verrier ER, Yim SA, Heydmann L, El Saghire H, Bach C, Turon-Lagot V, Mailly L, Durand SC, Lucifora J, Durantel D, Pessaux P, Manel N, Hirsch I, Zeisel MB, Pochet N, Schuster C, Baumert TF. (2018).
    Hepatitis B virus evasion from cGAS sensing in human hepatocytes.
    Hepatology. 68(5):1695-1709.
  106. Verrier ER, Weiss A, Bach C, Heydmann L, Turon-Lagot V, Kopp A, El Saghire H, Crouchet E, Pessaux P, Garcia T, Pale P, Zeisel MB, Sureau C, Schuster C, Brino L, Baumert TF. (2020).
    Combined small molecule and loss-of-function screen uncovers estrogen receptor alpha and CAD as host factors for HDV infection and antiviral targets.
    Gut. 69 (1): 158-167.
  107. Virzi A, Roca Suarez AA, Baumert TF, and Lupberger J (2018).
    Oncogenic Signaling Induced by HCV Infection.
    Viruses. Oct 2;10(10).
  108. Virzi A, Roca Suarez AA, Baumert TF and Lupberger J. (2020).
    Rewiring Host Signaling: Hepatitis C Virus in Liver Pathogenesis.
    Cold Spring Harb Perspect Med. 10(1): a037366.
  109. Vogel A, Cervantes A, Chau I, Daniele B, Llovet J, Meyer T, Nault JC, Neumann U, Ricke J, Sangro B, Schirmacher P, Verslype C, Zech CJ, Arnold D, Martinelli E. (2018).
    ESMO Guidelines Committee. Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
    Ann Oncol. 2018;29:iv238-iv255.
  110. Von Olshausen G, Quasdorff M, Bester R, Arzberger S, Ko C, van de Klundert M, Zhang K, Odenthal M, Ringelhan M, Niessen CM, Protzer U. (2018).
    Hepatitis B virus promotes β-catenin-signalling and disassembly of adherens junctions in a Src kinase dependent fashion.
    Oncotarget. Sep 21;9(74): 339547-60.
  111. Wakabayashi T, Ouhmich F, Gonzalez-Cabrera C, Felli E, Saviano A, Agnus V, Savadjiev P, Baumert TF, Pessaux P, Marescaux J, Gallix B. (2019).
    Radiomics in hepatocellular carcinoma: a quantitative review.
    Hepatol int. Sep;13(5):546-559.
  112. Wan S, Meyer AS, Weiler SME, Rupp C, Tóth M, Sticht C, Singer S, Thomann S, Roessler S, Schorpp-Kistner M, Schmitt J, Gretz N, Angel P, Tschaharganeh DF, Marquardt J, Schirmacher P, Pinna F, Breuhahn K. (2018).
    Cytoplasmic localization of the cell polarity factor scribble supports liver tumor formation and tumor cell invasiveness.
    Hepatology. 67(5):1842-1856.
  113. Wing PAC, Davenne T, Wettengel J, Lai AG, Chakraborty A, D’Arienzo V, Kramer C, Ko C, Harris JM, Schreniner S, Higgs M, Parish JL, Protzer U, Balfe P, Rehwinkel J and McKeating JA. (2019).
    A dual role for SAMDH1 in HBV cccDNA synthesis and RT-dependent particle genesis.
    Life Science Alliance. Mar 27;2(2).
  114. Wolski D, Foote PK, Chen DY, Lewis-Ximenez LL, Fauvelle C, Aneja J, Walker A, Tonnerre P, Torres-Cornejo A, Kvistad D, Imam S, Waring MT, Tully DC, Allen TM, Chung RT, Timm J, Haining WN, Kim AY, Baumert TF, Lauer GM. (2017).
    Early Transcriptional Divergence Marks Virus-Specific Primary Human CD8(+) T Cells in Chronic versus Acute Infection.
    Immunity. Oct 17;47(4):648-663.e8.
  115. Wrensch F, Crouchet E, Ligat G, Zeisel MB, Keck ZY, Foung SKH, Schuster C, Baumert TF.(2018).
    Hepatitis C Virus-Apolipoprotein Interactions and Immune Evasion and their impact on HCV vaccine design.
    Frontiers in Immunology. Jun 21;9:1436. Review.
  116. Wrensch F, Keck ZY, Foung SKH and Baumert TF. (2019).
    Learning from a clinical cohort for HCV vaccine development.
    J Hepatol. Jul;71(1):9-11. Review.
  117. Wu T, Heuillard E, Lindner V, Bou About G, Ignat M, Dillenseger JP, Anton N, Dalimier E, Gossé F, Fouré G, Blindauer F, Giraudeau C, El-Saghire H, Bouhadjar M, Calligaro C, Sorg T, Choquet P, Vandamme T, Ferrand C, Marescaux J, Baumert TF, Diana M, Pessaux P, Robinet E. (2016).
    Multimodal imaging of a humanized orthotopic model of hepatocellular carcinoma in immunodeficient mice.
    Sci Rep. Oct 14;6:35230.
  118. Xia Y, Cheng X, Blossey CK, Wisskirchen K, Esser K, Protzer U. (2017).
    Secreted Interferon-Inducible Factors Restrict Hepatitis B and C Virus Entry In Vitro.
    J Immunol Res. 4828936.
  119. Xia Y, Protzer U. (2017).
    Control of HBV virus by Cytokines.
    Viruses. 20:9(1), pii: E18.
  120. Zeisel MB and Baumert TF. (2016a).
    Hepatitis B virus: is a cure possible?
    Expert. Rev. Clin. Pharmacol. Sep;9(9):1129-30. Review.
  121. Zeisel MB and Baumert TF. (2016b).
    Translation and protein expression of lncRNAs: Impact for liver disease and hepatocellular carcinoma.
    Hepatology. 64, 671-674. Review.
  122. Zeisel MB and Baumert TF. (2016b).
    Tight junction proteins in gastrointestinal and liver disease.
    Hepatology. Oct 8. Review.
  123. Zeisel MB, Plissonnier ML, Levrero M. (2018).
    miR-122-regulated metabolic circuits: micro-management of lipid metabolism in the human liver.
    Non-Coding RNA Investigation. 2018 Oct;10(11). pii: E591. doi: 10.3390/v10110591. Review
  124. Zhang Z, Meszaros G, He WT, Xu Y, de Fatima Magliarelli H, Mailly L, Mihlan M, Liu Y, Puig Gámez M, Goginashvili A, Pasquier A, Bielska O, Neven B, Quartier P, Aebersold R, Baumert TF, Georgel P, Han J, Ricci R. (2017).
    Protein kinase D at the Golgi controls NLRP3 inflammasome activation.
    J Exp Med. Sep 4;214(9):2671-2693.
  125. Zhuang X, Magri A, Lai AG, Hill M, Chang WH, Donald C, Wing P, Brown R, Qin X, Parsons AL, Simmonds P, Roessler S, Baumert TF, Ray D, Loudon A, Balfe P, Butterworth S, Kohl A, Jopling CL, Zitzmann N and McKeating JA. (2019).
    The circadian clock BMAL1 and Rev-Erbα regulate flavivirus replication.
    Nature Comms. Jan 22;10(1):377.
  126. Zhuang X, Lai AG, McKeating JA, Rowe A and Balfe P. (2018).
    Daytime variation in hepatitis C virus replication kinetics post liver transplant.
    Wellcome Open Research. 3:96.
  127. Zhuang X, Rambhatla SB, Lai A and McKeating JA. (2017).
    Interplay between circadian clock and viral infection.
    J Molecular Medicine. 95; 1283-1289.